The Business Model

Our business model relates to drug development in neuropathic pain and Oncology where Ion Channel protein target(s) seem to be driving Tumour Initiating Cell (Cancer Stem cells) progression and maintenance of their tumorigenic and metastatic potential. 

Novassay develops novel leads in neuropathic pain and Oncology aiming to achieve clinical Proof of Concept (PoC, Phase II) in selected indications. Assets developed internally or in-licensed, are open to partnering for further clinical development.
Novassay has 100% exclusive ownership to all of its intellectual property portfolio.